denkapparat Operations GmbH Purchases 508 Shares of argenex SE $ARGX

denkapparat Operations GmbH increased its position in argenex SE (NASDAQ:ARGX) by 126.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 910 shares of the company’s stock after purchasing an additional 508 shares during the period. denkapparat Operations GmbH’s holdings in argenex were worth $844,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ARGX. Sands Capital Management LLC increased its stake in shares of argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after purchasing an additional 340,245 shares in the last quarter. Invesco Ltd. boosted its position in shares of argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after purchasing an additional 331,489 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares during the last quarter. Finally, Corient Private Wealth LLC increased its position in argenex by 12,441.8% during the 4th quarter. Corient Private Wealth LLC now owns 246,572 shares of the company’s stock valued at $207,355,000 after buying an additional 244,606 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

ARGX has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $1,150.00 price objective on shares of argenex in a research note on Thursday. Truist Financial increased their target price on argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings downgraded argenex from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 23rd. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Saturday, August 29th. Finally, UBS Group upgraded shares of argenex from a “neutral” rating to a “buy” rating and upped their price target for the stock from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average price target of $1,158.61.

argenex Stock Down 0.2%

ARGX opened at $1,053.46 on Friday. The stock has a market capitalization of $65.90 billion, a price-to-earnings ratio of 40.46, a PEG ratio of 1.09 and a beta of 0.47. The firm has a 50 day moving average price of $923.55 and a 200-day moving average price of $840.13. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. As a group, analysts expect that argenex SE will post 29.13 earnings per share for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.